The company entered into a multi-year agreement with U.S. Renal Care, the country’s largest privately held kidney care provider. They aim to utilize the Outset Tablo hemodialysis system as a home dialysis option in the 33 states in which U.S. Renal Care provides care.
Patients dialyzing with Tablo can easily learn the system and operate it in their home. Expanding treatment options through U.S. Renal Care can help meet the growing demand of dialysis patients seeking at-home treatment, Outset says.
“Our collaboration with U.S Renal Care is an important step forward in providing dialysis patients with options for where, when and how they want to dialyze,” said Leslie Trigg, chair and CEO of Outset Medical. “Tablo was specifically designed to reduce the complexity of dialysis and help restore the identity and agency of patients who must dialyze to survive. We are pleased to partner with U.S. Renal Care to advance this mission.”
Tablo is a fully integrated system for use across the care continuum and clinical spectrum, from the ICU to home hemodialysis treatments. It treats patients with acute and/or chronic renal failure, with or without ultrafiltration, in an acute or chronic care facility. All it requires is access to tap water and a standard electrical outlet.
“We have seen success using the Tablo system in our home hemodialysis program, and with our multi-year agreement with Outset, can continue providing our patients and caregivers access to lifesaving dialysis treatment in an easy-to-operate system, all in the comfort of their own homes,” added Steve Nottingham, U.S. Renal Care co-COO.
